Five Prime Therapeutics Inc. (NASDAQ:FPRX) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $50.39 and last traded at $49.27, with a volume of 240,265 shares traded. The stock had previously closed at $49.98.

Several research firms have recently commented on FPRX. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a research report on Sunday, May 8th. Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 20th. Jefferies Group restated a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Five Prime Therapeutics in a research note on Monday, April 18th. Finally, BMO Capital Markets assumed coverage on Five Prime Therapeutics in a research note on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $45.67.

The company has a market cap of $1.34 billion and a PE ratio of 5.60. The stock has a 50-day moving average price of $43.64 and a 200-day moving average price of $40.11.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.22. The business had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same period last year, the company posted ($0.44) earnings per share. The firm’s revenue for the quarter was up 51.2% on a year-over-year basis. On average, equities research analysts expect that Five Prime Therapeutics Inc. will post ($2.35) EPS for the current year.

In related news, Director Peder Jensen sold 12,195 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the completion of the sale, the director now directly owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

A number of institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its position in shares of Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock worth $1,744,000 after buying an additional 2,842 shares in the last quarter. ProShare Advisors LLC boosted its position in Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock valued at $1,055,000 after buying an additional 3,682 shares during the period. Russell Frank Co bought a new position in Five Prime Therapeutics during the fourth quarter valued at about $1,265,000. Finally, Marshall Wace LLP boosted its position in Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock valued at $9,841,000 after buying an additional 71,262 shares during the period.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.